EUVIMEDEUVIMED entdecken
Crossref

Monitoring the plasma concentration of ripretinib and its metabolites in Chinese patients with gastrointestinal stromal tumors in a real‐life setting

Qiang Zhang, Fengyuan Li, Feng Wang, Yongjian Zhou, Haoran Qian, Ming Wang, Xin Wu, Ye Zhou, Linsen Zhou, Luning Sun, Yongqing Wang, Zekuan Xu und 2 weitere

Cancer · 2025

DOI: 10.1002/cncr.70149 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Qiang Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, The Priority Academic Program Development of Jiangsu Higher Education Institutions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although therapeutic drug monitoring is crucial for the comprehensive management of gastrointestinal stromal tumors (GISTs), the relationship between plasma concentration of ripretinib and its therapeutic efficacy is unknown. This study aimed to explore the relationship between ripretinib plasma trough concentration (R‐C trough ) and clinical efficacy and between ripretinib concentration and the incidence of adverse reactions among Chinese patients with advanced GIST.

Methods

The authors analyzed patients with GIST treated continuously for ≥1 month with a consistent daily dose ripretinib in a real‐life setting. Peripheral venous blood samples were collected 24 h after the previous dose to measure R‐C trough and 4 h after the current dose to identify the maximum concentration (R‐C 4 ). The plasma concentrations of ripretinib and its metabolites were quantified using liquid chromatography‐tandem mass spectrometry.

Results

Between June 2021 and October 2024, 102 patients receiving ripretinib were evaluated. Ripretinib treatment resulted in higher mean R‐C trough values in the nonprogression group than in the progression group ( p < .05). Patients exhibiting an R‐C trough above the threshold (R‐C min , 475 ng/mL) demonstrated a significant improvement in median progression‐free survival from 12.8 to 22.6 months ( p < .05). A correlation was observed between ripretinib blood concentration and the occurrence of alopecia, fatigue, hand‐foot syndrome, and rashes ( p < .05). Moreover, variability in blood–drug concentrations was observed among patients with different KIT genotypes.

Conclusions

Ripretinib and its metabolites maintained consistent plasma concentrations in Chinese patients with advanced GIST. Furthermore, a trough ripretinib concentration >475 ng/mL was associated with extended survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsGastrointestinal NeoplasmsGastrointestinal Stromal TumorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedChinaDrug MonitoringProgression-Free SurvivalTandem Mass SpectrometryNaphthyridinesUreaEast Asian People

Stichwörter der Autor:innen

PFSTDMadverse drug reactiongastrointestinal stromal tumorripretinib

Substanzen

Antineoplastic AgentsripretinibNaphthyridinesUrea

Autor:innen und Institutionen

  • Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
  • Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
  • Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
  • Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of General Surgery, Chinese PLA General Hospital, Beijing, China.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • The Priority Academic Program Development of Jiangsu Higher Education Institutions
  • Jiangsu Key Medical Discipline
  • Collaborative Innovation Center for Cancer Personalized Medicine-Hengrui Research Fund
  • CSCO Zai Lab Cancer Research Fund
  • CSCO CSPC Cancer Research Fund

Zitieren

APA

Zhang, Q., Li, F., Wang, F., Zhou, Y., Qian, H., Wang, M., Wu, X., Zhou, Y., Zhou, L., Sun, L., Wang, Y., Xu, Z., Sun, X., & Xu, H. (2025). Monitoring the plasma concentration of ripretinib and its metabolites in Chinese patients with gastrointestinal stromal tumors in a real‐life setting. Cancer. https://doi.org/10.1002/cncr.70149

Vancouver

Zhang Q, Li F, Wang F, Zhou Y, Qian H, Wang M, et al. Monitoring the plasma concentration of ripretinib and its metabolites in Chinese patients with gastrointestinal stromal tumors in a real‐life setting. Cancer. 2025. doi:10.1002/cncr.70149

BibTeX
@article{Zhang2025,
  author = {Zhang, Qiang and Li, Fengyuan and Wang, Feng and Zhou, Yongjian and Qian, Haoran and Wang, Ming and Wu, Xin and Zhou, Ye and Zhou, Linsen and Sun, Luning and Wang, Yongqing and Xu, Zekuan and Sun, Xiaofeng and Xu, Hao},
  title = {Monitoring the plasma concentration of ripretinib and its metabolites in Chinese patients with gastrointestinal stromal tumors in a real‐life setting},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70149}
}
Kostenlos starten →